So far, DC plans have largely been focused on the onset of auto-enrolment and changes to the regulatory framework - be it the ‘charge cap, ‘pension freedoms or consultations around ‘value for money , says Annabel Tonry, Executive Director at J.P. Morgan Asset Management (JPMAM).Download
In 2015 George Osborne, then the UK Chancellor of the Exchequer, decided that those age over 55 could take much more of their pension in cash. This has since opened up a range of possibilities for DC scheme members in the world of pensions.Download
Find whitepapers
Ophthalmic Loupes Market Size Worth $668.3 Million By 2027: Grand View Research, Inc.
SAN FRANCISCO, Jan. 20, 2021 /PRNewswire/ The global ophthalmic loupes market size is expected to reach USD 668.3 million by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2020 to 2027. The growing prevalence of different eye diseases such glaucoma, cataract, and refractive errors is main factor expected to drive the overall market growth. Additionally, the growing usage of ophthalmic loupes in performing surgeries and for dental procedures due to its ability to provide higher magnification is expected to contribute towards the market growth.
Paramount Plus to Launch March 4 in U S and Latin America lmtonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lmtonline.com Daily Mail and Mail on Sunday newspapers.
Researchers find potential biomarkers of Parkinson s disease
A research team led by Nagoya University in Japan has found that blood pressure, hematocrit (the percentage of red blood cells in the blood), and serum cholesterol levels change in patients with Parkinson s disease long before the onset of motor symptoms.
This finding, which was recently published online in
Scientific Reports, may pave the way for early diagnosis and treatment of the disease.
Parkinson s disease, the second most common disease affecting the nervous system after Alzheimer s disease, is caused by a deficiency in a neurotransmitter called dopamine.
It is known that more than half of all dopaminergic neurons are already lost in patients with Parkinson s disease in the stage wherein they experience motor symptoms such as tremors, stiffness, and slowness of movement.